Oct 1, 2019
Thomas Lingelbach, CEO, Valneva talks about their work developing and commercializing vaccines for infectious diseases with unmet needs. This biotech company is in development of a Lyme disease vaccine and vaccines for mosquito-borne illnesses such as Zika and chikungunya. Thomas talks about the challenges of testing vaccines to prevent a disease within a healthy population and why it is impossible to eliminate all the vectors that can transmit a disease.
#Lyme #LymeDisease #chikungunya